Controlled trial of lovastatin combined with an open-label treatment of a parent-implemented language intervention in youth with fragile X syndrome

BACKGROUND: The purpose of this study was to conduct a 20-week controlled trial of lovastatin (10 to 40 mg/day) in youth with fragile X syndrome (FXS) ages 10 to 17 years, combined with an open-label treatment of a parent-implemented language intervention (PILI), delivered via distance video telecon...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Neurodev Disord
Autors principals: Thurman, Angela John, Potter, Laura A., Kim, Kyoungmi, Tassone, Flora, Banasik, Amy, Potter, Sarah Nelson, Bullard, Lauren, Nguyen, Vivian, McDuffie, Andrea, Hagerman, Randi, Abbeduto, Leonard
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2020
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7175541/
https://ncbi.nlm.nih.gov/pubmed/32316911
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s11689-020-09315-4
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars